Thrivent Financial for Lutherans Trims Position in Omnicell, Inc. (NASDAQ:OMCL)

Thrivent Financial for Lutherans reduced its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 5.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,118 shares of the company’s stock after selling 2,005 shares during the period. Thrivent Financial for Lutherans’ holdings in Omnicell were worth $1,575,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. GAMMA Investing LLC lifted its position in Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares during the last quarter. 1620 Investment Advisors Inc. lifted its holdings in shares of Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares during the period. CWM LLC boosted its stake in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after buying an additional 1,236 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Omnicell during the second quarter worth about $104,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Wells Fargo & Company boosted their price target on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. JPMorgan Chase & Co. lifted their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Benchmark reissued a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Barclays lifted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Wednesday. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $52.00.

Omnicell Stock Performance

NASDAQ:OMCL opened at $46.59 on Friday. The company has a fifty day moving average of $44.55 and a two-hundred day moving average of $37.94. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The stock has a market capitalization of $2.16 billion, a PE ratio of -119.46, a P/E/G ratio of 36.82 and a beta of 0.81.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.